Abstract
Atypical hemolytic uremic syndrome is a rare, life-threatening disorder which can be triggered by COVID 19 infection and COVID 19 vaccination then induce multiple organ failure. Our study is the first to evaluate immune responses to COVID-19 vaccination and safety in a cohort of patients in a local single-center study in Taiwan. Results indicate that vaccines effectively shield aHUS patients from severe COVID-19 complications without significant safety concerns. A double booster dose for the third vaccine is essential for optimal efficacy. Anti-complement therapy did not influence vaccination effectiveness. Transplant aHUS patients had the lowest immune response titers, indicating a need for additional vaccine doses. Compared to healthcare workers, aHUS patients had poor T-cell responses. We noted a superior trend with mixed-type COVID-19 vaccinations in aHUS patients, while fixed-type mRNA demonstrated better results in healthcare workers. Our findings endorse COVID-19 vaccination as a potent strategy to safeguard aHUS patients from severe complications, emphasizing the importance of vigilant monitoring pre- and post-vaccination.
Original language | English |
---|---|
Pages (from-to) | 5940-5945 |
Number of pages | 6 |
Journal | Vaccine |
Volume | 41 |
Issue number | 41 |
DOIs | |
State | Published - 22 09 2023 |
Externally published | Yes |
Bibliographical note
Copyright © 2023 Elsevier Ltd. All rights reserved.Keywords
- Atypical hemolytic uremic syndrome
- COVID-19
- Vaccination
- Vaccination/adverse effects
- Humans
- Taiwan
- COVID-19/prevention & control
- COVID-19 Vaccines/adverse effects
- Rare Diseases
- Atypical Hemolytic Uremic Syndrome